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OBJECTIVE—To determine the role of hepatocyte growth
factor (HGF)/c-Met on b-cell survival in diabetogenic conditions
in vivo and in response to cytokines in vitro.
RESEARCH DESIGN AND METHODS—We generated pancreas-
speciﬁc c-Met-null (PancMet KO) mice and characterized their
response to diabetes induced by multiple low-dose streptozotocin
(MLDS) administration. We also analyzed the effect of HGF/c-Met
signaling in vitro on cytokine-induced b-cell death in mouse and
human islets, speciﬁcally examining the role of nuclear factor
(NF)-kB.
RESULTS—Islets exposed in vitro to cytokines or from MLDS-
treated mice displayed signiﬁcantly increased HGF and c-Met
levels, suggesting a potential role for HGF/c-Met in b-cell survival
against diabetogenic agents. Adult PancMet KO mice displayed
normal glucose and b-cell homeostasis, indicating that pancreatic
c-Met loss is not detrimental for b-cell growth and function under
basal conditions. However, PancMet KO mice were more suscep-
tible to MLDS-induced diabetes. They displayed higher blood glu-
cose levels, marked hypoinsulinemia, and reduced b-cell mass
compared with wild-type littermates. PancMet KO mice showed
enhanced intraislet inﬁltration, islet nitric oxide (NO) and chemo-
kine production, and b-cell apoptosis. c-Met-null b-cells were more
sensitive to cytokine-induced cell death in vitro, an effect mediated
by NF-kB activation and NO production. Conversely, HGF treat-
ment decreased p65/NF-kB activation and fully protected mouse
and, more important, human b-cells against cytokines.
CONCLUSIONS—These results show that HGF/c-Met is critical
for b-cell survival by attenuating NF-kB signaling and suggest that
activation of the HGF/c-Met signaling pathway represents a novel
strategy for enhancing b-cell protection. Diabetes 60:525–536,
2011
T
ype I diabetes is an autoimmune disease that
results from cellular cytotoxicity leading to se-
lective and progressive destruction of insulin-
secreting cells (1–3). Many growth factors
known to control cell growth and survival in physiologic
and pathologic conditions are expressed in the pancreas
and could potentially participate in an autocrine/paracrine
fashion in the ﬁnal fate of b-cells in an autoimmune envi-
ronment. Overexpression of IGF-1, transforming growth
factor-b, or granulocyte macrophage-colony stimulating
factor ameliorates islet inﬁltration and b-cell death in
mouse models of increased islet inﬂammation and diabetes
(4–6). However, the role of endogenous pancreatic growth
factors in type I diabetes has not been examined. Because
growth factors can locally affect b-cell survival, neo-
genesis, and regeneration, and modulate chemokine pro-
duction and immune responses, alterations in the level/
activation of growth factor signaling pathways might
contribute to the delay/acceleration of the onset of di-
abetes.
Hepatocyte growth factor (HGF)/c-Met signaling path-
way participates in the control of multiple biological
functions, including development, proliferation, survival,
regeneration, and branching morphogenesis (7). HGF
binds with high afﬁnity to, and induces the dimerization of,
c-Met, its transmembrane tyrosine kinase receptor (8).
Deletion of exon 16 of the c-Met gene, which encodes
Lys
1108 (ATP binding site), essential for the kinase activity
of this receptor, in knockout mice results in embryonic
lethality (9). These mice display a phenotype identical to
HGF knockout mice (10). Both HGF and c-Met are
expressed in the pancreas; HGF localizes to endothelial,
islet, and mesenchymal cells, and c-Met is expressed in
islet, ductal, and pancreatic progenitor cells (11–14).
Conditional ablation of the c-Met gene in mouse b-cells
using RIP-Cre and lox-c-Met mice leads to deﬁcient insulin
secretion without alteration of b-cell mass (12,13). On the
other hand, HGF overexpression in the b-cell of transgenic
mice increases b-cell replication, mass, and function
(15,16). Furthermore, HGF improves islet graft survival in
animal models of diabetes (17–19). HGF positively inﬂu-
ences autoimmune responses, reducing the severity of
autoimmune myocarditis and arthritis (20,21). HGF also
downregulates airway and kidney inﬂammation, and in-
ﬂammatory bowel disease (22–24). Whether HGF plays
a role in autoimmune diabetes is unknown.
To address the function of c-Met in the development,
growth, and maintenance of b-cells under physiologic
conditions, as well as its role in b-cell survival and re-
sponse to injury in vivo, we generated pancreas-speciﬁc
c-Met-null (PancMet KO) mice. We report that although
c-Met is dispensable for normal b-cell growth and function
under basal conditions, it is critically important for b-cell
survival in diabetogenic conditions. b-Cell survival is dra-
matically worsened in the absence of HGF/c-Met signaling,
resulting in accelerated diabetes onset. These observations
also apply to human b-cells, underscoring a therapeutic
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RESEARCH DESIGN AND METHODS
Generation of c-Met conditional knockout mice in the pancreas. Mice
homozygous for the ﬂoxed c-Met allele (25) were crossed with Pdx-Cre
transgenic mice (26). The resultant double-heterozygous mice were then
crossed with c-Met
lox/lox mice, resulting in c-Met
lox/lox, Pdx-Cre (PancMet KO)
mice, and their wild-type (WT) littermates c-Met
lox/lox or c-Met
lox/+ without
Pdx-Cre transgene. Genotyping and assessment of deletion efﬁciency were
analyzed by PCR on genomic DNA obtained from tails or pancreas (12,26). All
the studies were performed with the approval of, and in accordance with,
guidelines established by the University of Pittsburgh Institutional Animal
Care and Use Committee.
Glucose homeostasis in adult PancMet KO mice in basal conditions.
Blood obtained by retro-orbital bleed was analyzed for glucose by a portable
glucometer (Medisense, Bedford, MA), and plasma insulin was analyzed by
radioimmunoassay (Linco Research, St. Louis, MO) (15). Intraperitoneal glu-
cose tolerance test was performed in 16–18-h fasted mice injected in-
traperitoneally (IP) with 2 g glucose/kg body wt, and insulin sensitivity tests
were performed in mice in the random-fed state injected IP with 0.75 units
bovine insulin/kg body wt (12). Insulin content in islets or pancreas, and
glucose-stimulated insulin secretion in isolated islets were measured as
reported (12).
Multiple low-dose streptozotocin-induced diabetes. Male mice aged 10–12
weeks were injected IP for 5 consecutive days with streptozotocin (STZ) (40
mg/kg) (27), starting at day 0, and nonfasting blood glucose was measured
from snipped tails at different time points.
Immunohistochemistry and insulitis. Parafﬁn-embedded pancreatic sec-
tions were immunostained for insulin, glucagon, somatostatin, c-Met, and 5-
bromo-2’-deoxyuridine (BrdU) as described (12,15). b-Cell mass and islet
number were measured in three insulin-stained pancreas sections from each
mouse using ImageJ (National Institutes of Health, Bethesda, MD) (12). BrdU
incorporation in b and ductal cells was measured in pancreas sections of mice
injected IP with BrdU (Amersham, Piscataway, NJ), killed 6 h later, and stained
for insulin and BrdU (12). b-Cell death was determined in pancreas sections
stained for insulin and using the terminal deoxynucleotidyl transferase-
mediated dUTP nick end-labeling (TUNEL) method (Promega, Madison, WI).
Sections were also stained with hematoxylin–eosin and anti-CD3 (Abcam,
Cambridge, MA) for pathologic evaluation of islet insulitis (28).
Islet isolation and culture of pancreatic islets and bTC-3 cells. Mouse
islets were isolated after injection of collagenase P through the pancreatic duct,
as previously reported (12). Human islets were provided by the ICR and JDRF
Basic Science Islet Distribution Programs. Individual mouse and human islets
were hand-picked under a stereomicroscope, and 100–200 islets/mL were
cultured in Roswell Park Memorial Institute medium in the presence or ab-
sence of recombinant mouse or human cytokines: interleukin (IL)-1b (5–500
units/mL), interferon (IFN)-g (100–1,000 units/mL), and tumor necrosis factor
(TNF)-a (100–1,000 units/mL), respectively.
Analysis of c-Met, HGF, inducible nitric oxide-synthase (iNOS), and A20
mRNA expression in isolated islets was performed by real-time PCR using
speciﬁc primers (Supplementary Table 1) (29). In a different set of real-time
PCR experiments, mouse insulinoma bTC-3 cells were plated (50–100 3 10
3
cells/cm
2) in Dulbecco’s modiﬁed Eagle’s medium with 10% fetal bovine se-
rum. Twenty-four hours later, cells were serum depleted and treated with 1
mmol/L STZ or 50 units/mL IL-1b, 1,000 units/mL IFN-g, and 1,000 units/mL
TNF-a for 16 h before harvesting and RNA isolation.
Medium nitric oxide, monocyte chemoattractant protein-1, and monokine
induced by g-IFN concentration measurements. Medium (100 mL) from
islet cultures containing 100 islets/mL was analyzed for nitric oxide (NO) by
adding an equal volume of Greiss reagent (28). Monocyte chemotactic pro-
tein (MCP)-1 and monokine induced by g-IFN (MIG) concentrations in me-
dium were determined using a speciﬁc ELISA (R&D Systems, Minneapolis,
MN).
Western blot analysis. Human and mouse islet extracts were separated on
7.5–10% SDS/PAGE, transferred to an Immobilon-P membrane (Millipore,
Bedford, MA), blocked in 5% nonfat dry milk, and then incubated with pri-
mary antibodies against phospho-Ser536 p65, phospho-Ser32/36 IкBa,I кBa,
phospho-Ser9 GSK3b, phospho-Ser473-AKT, phospho-ERK1/2, ERK1/2 (Cell
Signaling, Beverly, MA), iNOS, p65, c-Met (Santa Cruz Biotechnology, Santa
Cruz, CA), tubulin, and HGF (Calbiochem, La Jolla, CA). After several washes,
blots were incubated with peroxidase-conjugated secondary antibodies fol-
lowed by chemiluminescence detection (Amersham) (12).
Islet cell cultures and determination of b-cell death. Mouse and human
islet cells were cultured as previously reported (30) and incubated with dif-
ferent doses of cytokines, STZ, or HGF for a period of 24 h and then ﬁxed in 2%
paraformaldehyde. b-Cell death was determined by TUNEL assay and insulin
and DAPI staining. At least 2,000 b-cells per treatment were counted.
p65/NF-kB binding activity assay. Activation and binding of p65/NF-kB were
quantiﬁed using an ELISA-based TransAM p65 kit (Active Motif, Carlsbad, CA).
Brieﬂy, protein extracts from human islets treated for 10 min with cytokines,
HGF, or 10 nM Wortmannin were added to a 96-well plate with an immobilized
oligonucleotide containing an NF-kB consensus binding site. Activated NF-kB
homodimers and heterodimers contained in the islet extracts bind speciﬁcally
to this oligonucleotide. p65 antibody was then added, followed by horseradish
peroxidase-conjugated secondary antibody. Binding activity of p65/NF-kBw a s
determined by measuring absorbance at 450 nm with a reference wavelength
of 655 nm and expressed as –fold of untreated islets.
Statistical analysis. Data are presented as means 6 SE. Statistical analysis
was performed using unpaired two-tailed Student t test, one-way ANOVA with
Tukey’s honestly signiﬁcant difference post hoc test where indicated, Fisher
exact test for the analysis of percent of hyperglycemic mice, and Pearson x
2
test for analysis of insulitis. In all the tests, P , 0.05 was considered statisti-
cally signiﬁcant.
RESULTS
HGF and c-Met expression increase in islets after
multiple low-dose streptozotocin administration in
vivo and after treatment with cytokines in vitro. The
multiple low-dose streptozotocin (MLDS) model is a di-
abetogenic model in which hyperglycemia and diabetes
are achieved after ﬁve daily injections of subdiabetogenic
doses of STZ, leading to insulitis and selective b-cell loss
(27). At day 5 after the ﬁrst STZ injection, islets from mice
treated with MLDS displayed signiﬁcantly increased HGF
and c-Met mRNA expression (Fig. 1A). Mouse islets treated
with 1 mmol/L STZ for 24 h in vitro display increased HGF,
but not c-Met, mRNA expression (Fig. 1B). Mouse islets
and bTC-3 insulinoma cells treated in vitro with a combi-
nation of cytokines for 16–24 h showed increased c-Met,
but not HGF mRNA expression (Fig. 1C and D). This
suggests that in the MLDS-treated mouse islets, perhaps
both STZ and inﬂammation are upregulating HGF and
c-Met mRNA. Both HGF and c-Met proteins are upregu-
lated in MLDS-treated mouse islets in vivo and in mouse
islets treated with cytokines in vitro (Fig. 1E and F). This
latter result suggests that posttranscriptional alterations
might be responsible for HGF accumulation in mouse
islets treated with cytokines. Collectively, these data sug-
gest that islet and b-cell damaging agents, such as islet
inﬂammation and STZ, induce the expression of both c-Met
and its ligand HGF.
Generation and characterization of PancMet KO
mice. We generated conditional KO mice (PancMet KO
mice) with selective elimination of c-Met expression in
pancreas and islets by combining Pdx-Cre with c-Met
lox/lox
mice (Fig. 2A). Compared with WT (c-Met
lox/lox or c-Met
lox/+)
mice, PancMet KO mice exhibit efﬁcient Cre-mediated
exon 16 deletion, and decreased c-Met levels, as assessed
by PCR analysis of pancreas genomic DNA and Western
blot of pancreas and islet protein extracts (Fig. 2B–D). The
detection of c-Met expression in pancreas extracts from
PancMet KO mice could be due to the presence of c-Met in
nonendocrine and nonexocrine cell types, such as vascular
cells, ﬁbroblasts, immune cells, and cells in lymph nodes,
all of which are present in the pancreas. PancMet KO mice
display marked downregulation of c-Met in islets and ducts
as assessed by immunoﬂuorescent staining (Fig. 2E–H).
Furthermore, HGF-mediated signaling via ERK1/2 was
markedly attenuated in PancMet KO mouse islets (Fig. 2I).
Taken together, these results indicate that PancMet KO
mice display effective and efﬁcient recombination of c-Met
in pancreas and islets. Notably, c-Met deﬁciency in the
pancreas and b-cells of adult mice did not signiﬁcantly
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display lower nonfasting blood glucose was observed in
PancMet KO mice (Supplementary Figs. 1 and 2). In ad-
dition to being expressed in insulin-positive cells, c-Met is
also present in glucagon- and somatostatin-positive cells
in mouse islets (Supplementary Fig. 3), and its absence
could lead to alterations in the proportion of these endo-
crine cells in PancMet KO mice. Analysis of a-cell/b-cell
and d-cell/b-cell ratios per islet reveals normal values in
PancMet KO mice (Supplementary Fig. 2I and J). These
results show that HGF actions in the pancreas are dis-
pensable for a-, d-, and b-cell growth, and b-cell mainte-
nance and function under basal conditions.
PancMet KO mice are more susceptible than WT mice
to MLDS-induced diabetes. Because c-Met and HGF are
upregulated in islets after exposure to cytokines in vitro or
after MLDS treatment in vivo (Fig. 1), we sought to address
the functional importance of c-Met in the adaptive
responses of the b-cell to the injury induced by MLDS
administration in vivo. We measured blood glucose levels
in PancMet KO and WT mice during 20 days after the ﬁrst
STZ injection. MLDS-treated PancMet KO mice displayed
signiﬁcantly increased blood glucose levels compared with
WT mice from day 4 to day 20 (Fig. 3A). In addition, MLDS-
treated PancMet KO mice displayed a nonsigniﬁcant trend
toward faster and higher frequency of hyperglycemia
compared with WT mice (Fig. 3B).These results correlated
with signiﬁcant hypoinsulinemia in PancMet KO mice at day
20 after the ﬁrst STZ injection compared with the reduced
insulin levels in WT mice treated with MLDS (Fig. 3C).
Together with a more pronounced deterioration in glu-
cose homeostasis after MLDS administration, PancMet KO
mice also displayed signiﬁcantly decreased b-cell mass (Fig.
4A–C). This decrease was not due to diminished number of
islets or decreased b-cell neogenesis, measured as the
number of singlet and doublet insulin-positive cells in the
pancreas (Supplementary Fig. 4), but to a reduction of
insulin-positive area per islet (Fig. 4D–F). The number of
islets with .80% insulin-positive area was markedly and
signiﬁcantly decreased in PancMet KO mice compared with
WT littermates (Fig. 4F). Conversely, the number of islets
with ,20% insulin-positive area was signiﬁcantly increased
in PancMet KO mice, suggesting a decrease in the number
of insulin-positive cells per islet in these mice. An increase
in b-cell death would likely explain the decrease in insulin-
positive cells per islet and the diminished b-cell mass in
PancMet KO mice compared with WT littermates. Indeed,
t h ep e r c e n t a g eo fT U N E L - p o s i t i v eb-cells at day 8 after the
FIG. 1. A: Expression of HGF and c-Met mRNA in islets obtained from mice after 5 days of MLDS (40 mg/kg) administration (n = three mice/group).
HGF and c-Met mRNA expression in islets treated in vitro (B) with 1 mmol/L STZ for 24 h or (C) with 50 units/mL of IL-1b, 1,000 units/mL TNF-a,
1,000 units/mL IFN-g for 24 h, and (D)i nbTC-3 insulinoma cells treated with the same concentration of cytokines for 16 h. Real-time PCR results
are mean 6 SEM of three experiments in triplicate. *P < 0.05 vs. untreated. HGF and c-Met protein expression (E) in islets obtained from mice
after 5 days of MLDS administration and (F) in islets treated in vitro with 1,000 units/mL TNF-a, 1,000 units/mL IFN-g, and 50 or 100 units/mL of
IL-1b for 24 h. Western blot results are representative of three different experiments.
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in PancMet KO mice, even when compared with the ex-
pected cell death in WT mice treated with MLDS (Fig. 4G–I).
PancMet KO mice display increased lymphocyte in-
ﬁltration in response to MLDS. To determine whether
the increased sensitivity of PancMet KO mice to the diabe-
togenic effects of MLDS was associated with exaggerated
insulitis, hematoxylin–eosin-stained pancreatic sections
from MLDS-treated mice were examined histologically for
the degree of insulitis based on the scale described by
Flodström et al. (28): 0, no inﬁltration; 1, mild inﬁltration;
2, minor peri-insular inﬁltration; 3, clear peri-insular in-
ﬁltration; 4, clear intraislet inﬁltration. PancMet KO mouse
islets displayed clear intraislet inﬁltration that also
strongly stained with an anti-CD3 antibody, a general
marker for lymphocytes (Fig. 5A–D). Determination of
insulitis degree showed that the number of islets without
inﬁltration was signiﬁcantly decreased, and the number of
islets with clear inﬁltration was signiﬁcantly increased, in
PancMet KO compared with WT mice (Fig. 5E).
Chemokines and cytokines are mediators of the immune
response by attracting and activating leukocytes. Because
FIG. 2. Assessment of exon 16 deletion and c-Met downregulation in pancreas and islets of PancMet KO mice. A: Schematic illustration of Cre-
mediated deletion of exon 16 from the c-Met allele. Cre action removes exon 16 and intron sequences between the two LoxP sites (white
arrowheads). E: EcoRI restriction sites; P1 (LoxP) and P2 (exon 16) primers used for genotyping and assessment of c-Met deletion from pancreas
genomic DNA. B: PCR analysis of pancreas genomic DNA from WT and PancMet KO mice. PCR fragments corresponding to ﬂoxed c-Met alleles (600
bp), GADPH (259 bp), and Cre (332 bp) are shown. Western blot of c-Met expression in (C) pancreas and (D) islet protein extracts from WT and
PancMet KO mice. E–H: Immunoﬂuorescent staining for c-Met on pancreatic sections from WT and PancMet KO mice. A profound decrease in
c-Met staining was observed in (F) islets and (H) cells lining the duct (duct lumen labeled with *) of PancMet KO mice compared with WT mice
(E and G). Scale bar = 50 mm. I: Western blot of ERK1/2 activation in isolated islets from WT and PancMet KO mice treated with 25 ng/mL HGF.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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tion, we measured the level of the secreted chemokines
MCP-1 and MIG from PancMet KO and WT mouse islets
exposed to cytokines. As shown in Fig. 5F and G, cytokine-
induced chemokine secretion is signiﬁcantly increased in
PancMet KO compared with WT mouse islets.
PancMet KO b-cells are more sensitive to STZ- and
cytokine-mediated cell death. The results presented thus
far indicate that b-cells deﬁcient in c-Met are more sensitive
to cell death in vivo after MLDS administration, but they do
not address whether they are more sensitive to the initial
cytotoxic effects of STZ, the concomitant inﬂammatory
insult generated in this model, or both. To directly address
this issue, we performed TUNEL and insulin staining of
primary islet cell cultures from WT and PancMet KO mice
treated with STZ or cytokines in vitro. b-Cell death was
signiﬁcantly increased in PancMet KO islet cell cultures
treated with STZ or cytokines compared with WT cells
(Fig. 6A–D).
Inhibition of NF-kB activation eliminates the increased
sensitivity of PancMet KO b-cells to cytokine-mediated
cytotoxicity. Accumulating evidence suggests that the
transcription factor NF-kB is an important intracellular me-
diator initiating the cascade of events that lead to b-cell
death in the presence of cytokines (31–33). Therefore, we
examined activation of NF-kB as measured by phosphory-
lated p65/RelA in cytokine-treated islets and found enhanced
phospho-p65 levels in PancMet KO mouse islets compared
with WT islets (Fig. 6E and F). iNOS is a well-known NF-kB
target gene induced by cytokines (31,34,35). To determine
whether iNOS induction was greater in c-Met-null islets, we
measured iNOS mRNA and protein expression, and NO
formation as nitrite accumulation in the culture media of
cytokine-treated PancMet KO and WT islets. PancMet KO
mouse islets displayed signiﬁcantly increased iNOS expres-
sion levels and NO production compared with WT islets (Fig.
6G–J). In addition, another NF-kB target gene A20, a pro-
survival gene in b-cells (36), was also further induced
in PancMet KO islets compared with WT islets (Fig. 6G).
Collectively, these data conﬁrm the increased cytokine-
mediated activation of NF-kB in PancMet KO islets. The
addition of the NOS inhibitor L-N
G-monomethyl Arginine
(L-NMMA) (Fig. 6K)o rt w od i f f e r e n tN F - kB inhibitors, so-
dium salicylate, which binds to and inhibits NF-kB activator
IkB kinase (IKK) b (37), or the cell-permeable peptide SN-50,
which inhibits the nuclear translocation of the NF-kB active
complex (38), completely blocked the increased sensitivity
of PancMet KO b-cells to the cytotoxic effects of cytokines
(Fig. 6L). However, SN-50 did not alter STZ-mediated cyto-
toxicity in PancMet KO b-cells (Supplementary Fig. 5A).
FIG. 3. PancMet KO mice treated with MLDS display (A) signiﬁcantly increased blood glucose levels (^P < 0.05 vs. WT) and (B) a trend toward
faster and higher frequency of hyperglycemia (>200 mg/dL on at least two consecutive measurements), although not signiﬁcant (P = 0.084 at day 12
and P = 0.154 at days 16 and 20 determined by Fisher exact test). On the other hand, PancMet KO mice display a signiﬁcantly faster and higher
frequency of severe hyperglycemia (>300 mg/dL on at least two consecutive measurements) compared with WT mice (day 16, PancMet KO 100% vs.
WT 10%, P = 0.002; day 20, PancMet KO 100% vs. WT 20%, P = 0.007). C: PancMet KO mice treated with MLDS display profound hypoinsulinemia at
day 20 (*P < 0.05 vs. untreated and ^P < 0.05 vs. WT). WT (n = 10) and PancMet KO mice (n = 5) were injected with 40 mg/kg STZ for 5 days.
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equally sensitive to cytokines + FasL (Jo-2) cell death stim-
ulus (Supplementary Fig. 5B). These results suggest that in-
creased NF-kB activation and NO production in PancMet KO
islets affect cytokine-induced but not Fas/FasL- or STZ-
mediated b-cell death, and that proapoptotic genes induced
by NF-kB counteract the potential prosurvival effects of A20
in c-Met-null b-cells.
HGF decreases NF-kB activation and protects rodent
and human b-cells against cytokines. To ascertain
whether activation of the HGF/c-Met signaling pathway
protects b-cells from cytokines, we added HGF to nor-
mal mouse primary islet cell cultures treated with in-
creasing doses of cytokines and analyzed the percentage
of TUNEL-positive b-cells. HGF completely protected nor-
mal mouse b-cells against cytokines (Fig. 7A), but not
PancMet KO b-cells, suggesting that HGF-induced pro-
tective effects are mediated through c-Met (Supplementary
Fig. 6). Opposite to what was observed in PancMet KO
islets, normal cytokine-treated islets incubated with HGF
displayed signiﬁcantly decreased NF-kB activation (Fig. 7B
and C), iNOS expression (Fig. 7D and E), and NO pro-
duction (Fig. 7F). Collectively, these results in PancMet KO
b-cells and in islets treated with HGF indicate that HGF may
protect mouse b-cells against cytokine-induced cell death
by inactivation of NF-kB and decreased NO production.
More important, HGF completely protected human
b-cells from cytokine-induced cell death (Fig. 8A–C) and
signiﬁcantly decreased p65/RelA phosphorylation in hu-
man islets (Fig. 8D and E). Activation of p65/NF-kB and
binding to an NF-kB consensus sequence were also in-
hibited by HGF in human islets (Fig. 8F). Furthermore,
FIG. 4. Decreased b-cell mass and increased b-cell death in PancMet KO mice treated with MLDS. A and B: Representative photomicrographs of
pancreas sections obtained from MLDS-treated mice (day 20) stained for insulin (brown) and counterstained with hematoxylin. Scale bar = 200
mm. C: Histomorphometric quantitation of b-cell mass in three pancreatic sections per mouse separated by 50 mm and stained for insulin. Pan-
creata were harvested at day 20 after MLDS from PancMet KO (n = 5) and WT (n = 10) mice. D and E: Photomicrographs of representative islets
from PancMet KO and WT littermates treated with MLDS and stained for insulin. Scale bar = 50 mm. F: Percentage of islets with insulin-positive
areas ranging from >80 to <20% assessed in three pancreatic sections from WT (n = 10) and PancMet KO mice (n = 5) 20 days after MLDS
treatment. G and H: Representative photomicrographs of islets from PancMet KO and WT littermates at day 8 after treatment with MLDS and
stained for insulin (red) and TUNEL (green). Scale bar = 50 mm. A higher magniﬁcation photo of an area in the pancreas of PancMet KO mice is
displayed on the right side of H. Arrows indicate TUNEL-positive b-cell nuclei. I: Quantitation of TUNEL-positive b-cell nuclei in pancreatic
sections from PancMet KO (n = 5) and WT (n = 5) mice treated with MLDS and harvested at day 8. *P < 0.05 and **P < 0.01 vs. untreated and ^P <
0.05 vs. WT. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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of NF-kB activation that are involved in cytokine-mediated
b-cell death, signiﬁcantly decreasing the phosphorylation
of inhibitor of k-B (IkB) a and increasing the phosphory-
lation of AKT and GSK-3b in cytokine-treated human islets
(Fig. 8D and E) (39,40). HGF-mediated inhibition of NF-kB
activation in islets was signiﬁcantly decreased by the PI3K
inhibitor Wortmannin (Fig. 8F). Taken together, these re-
sults suggest that HGF may protect human b-cells against
cytokine-induced cell death by inactivation of the NF-kB
and activation of the PI3K/Akt signaling pathways.
DISCUSSION
The current study provides the ﬁrst direct evidence that
endogenous pancreatic HGF/c-Met signaling is important
for b-cell survival in diabetogenic conditions. On one hand,
the absence of c-Met in the mouse pancreas enhances
b-cell death, islet chemokine and NO production, insulitis,
and b-cell mass depletion, leading to further pronounced
hypoinsulinemia, further increased blood glucose levels,
and a nonsigniﬁcant trend toward faster and higher fre-
quency of hyperglycemia in response to MLDS treatment.
On the other hand, HGF protects rodent and, more im-
portant, human b-cells from cytokine-induced cell death.
Therefore, these observations indicate that activation of
the HGF/c-Met signaling pathway attenuates b-cell death
and identiﬁes this pathway as a therapeutic target for the
treatment of the disease.
PancMet KO mice display normal glucose and b-cell ho-
meostasis, suggesting that HGF actions in the pancreas are
dispensable for b-cell growth, maintenance, and function
under basal conditions. This is in contrast with our previous
results indicating that elimination of c-Met from b-cells
in RIP-Cre-lox-Met mice leads to mildly impaired glucose
tolerance and decreased glucose-stimulated insulin se-
cretion (12). Because heterozygote RIP-Cre mice (CD-1
background) used in our studies display normal glucose
homeostasis (not shown), there are two possible reasons
for the difference in the metabolic phenotype between
RIP-Cre-lox-Met mice and PancMet KO mice: 1) the dif-
ferential elimination of c-Met from b-cells in one case and
from pancreatic precursors that give rise to endocrine,
exocrine, and ductal cells in the other; or 2) because the
RIP-Cre transgene is also expressed in the hypothalamus
(41), the metabolic defects observed in RIP-Cre-lox-c-Met
FIG. 5. Increased degree of intraislet inﬁltrate in PancMet KO mice treated with MLDS compared with WT littermates. Hematoxylin–eosin (A and
B) and anti-CD3 (C and D) staining of pancreas sections from MLDS-treated mice. A representative islet from a PancMet KO mouse showing
severe lymphocyte intraislet inﬁltration compared with an islet from WT mice displaying mild lymphocyte inﬁltration. Scale bar = 50 mm. E: Degree
of insulitis at day 20 after MLDS administration in WT (n = 10) and PancMet KO (n = 5) mice. Insulitis was calculated as percent of islets per
mouse in each stage of insulitis (0–4 as described in RESULTS). Secreted chemokines MCP-1 (F) and MIG (G) accumulated in the media of islets
exposed to cytokines 50 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g for 24 h. Data pooled from ﬁve different experiments are
shown (n = 10 WT and n = 10 PancMet KO mice). *P < 0.05 vs. untreated and ^P < 0.05 vs. WT. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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diabetes.diabetesjournals.org DIABETES, VOL. 60, FEBRUARY 2011 531FIG. 6. Increased sensitivity of PancMet KO b-cells to STZ- or cytokine-induced cell death is mediated by NF-kB activation. A and B: Represen-
tative photomicrographs of islet cultures treated with STZ for 24 h and stained for TUNEL (green), insulin (red), and DAPI (blue). Arrows indicate
TUNEL-positive b-cell nuclei. Scale bar = 25 mm. Quantitation of TUNEL-positive b-cell nuclei in ﬁve experiments performed in duplicate of islet
cell cultures of PancMet KO and WT mice treated with (C) STZ or (D) 50 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g for 24 h.
E: Representative Western blot displaying phospho-p65 and p65 expression in protein extracts from PancMet KO and WT islets treated with or
without 50 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g. F: Densitometric quantitation of phospho-p65 and p65 in ﬁve Western
blots performed with ﬁve different islet extract samples per time point. G: mRNA expression of iNOS and A20, two NF-kB target genes, in islets
from WT (n = 4), and PancMet KO (n = 5) mice treated with or without cytokines (5 units/mL IL-1b, 100 units/mL TNF-a, and 100 units/mL IFN-g)
for 6 h. H: Representative Western blot displaying iNOS and tubulin expression in protein extracts from PancMet KO and WT islets treated with or
without 50 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g for 24 h. I: Densitometric quantitation of iNOS expression in three
Western blots performed with three different islet extract samples per condition. J: Medium nitrite levels secreted from islets exposed in vitro to
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b-cells but also from the hypothalamus.
HGF is a prosurvival agent in multiple cell types, in-
cluding the b-cell (7,8,15–19). HGF increases b-cell sur-
vival in vivo after administration of high doses of STZ, as
well as in an islet transplant setting in diabetic mice in
which hypoxia- and nutrient deprivation-mediated b-cell
damage are present (15–19). In vitro, exogenously added
HGF protects b-cells against STZ (17). The current study
found that HGF also protects both mouse and human
b-cells against high doses of cytokines. HGF and c-Met are
both upregulated in islets at early stages (day 5) in the
MLDS mouse model and in vitro after cytokine and STZ
treatment. This suggests that STZ and islet inﬂammation
activate the HGF/c-Met pathway in islet cells, and poten-
tially in islet inﬁltrating cells (20–24,42), perhaps in an
attempt to counteract the damage induced by these cyto-
toxic agents. Indeed, removal of HGF/c-Met signaling from
islets renders b-cells more sensitive to STZ and cytokines
in vitro and, more important, leads to exacerbated b-cell
death, further increased blood glucose levels, and a non-
signiﬁcant trend toward faster and higher frequency of
hyperglycemia in the MLDS mouse model. This indicates
that the autocrine action of the upregulated HGF/c-Met
system, or the paracrine or endocrine HGF from other
sources (43,44), might participate in delaying b-cell death
FIG. 7. Protective effect of HGF on primary mouse b-cells treated with cytokines. A: Mouse islet cell cultures were treated with or without 25 ng/
mL HGF and 100 or 500 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g for 24 h. Results are means 6 SE of ﬁve experiments in
duplicate. B: Representative Western blot displaying phospho- and total p65 levels in protein extracts from mouse islets treated with or without 25
ng/mL HGF and 100 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g for different time periods. C: Densitometric quantitation of
phospho- and total p65 in four Western blots performed with four different protein extracts. D: Representative Western blot displaying iNOS and
tubulin levels in protein extracts from mouse islets treated with or without the same doses of cytokines and HGF for 24 h. E: Densitometric
quantitation of iNOS expression in three Western blots performed with three different protein extracts. F: Medium nitrite levels secreted from
islets treated with or without the same doses of cytokines and HGF for 24 h. *P < 0.05 vs. untreated and ^P < 0.05 vs. cytokine-treated but HGF-
untreated cells. CKS, cytokines.
50 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g for 24 h. Effect of the NOS inhibitor L-NMMA citrate (2 mmol/L) (K) and the
NF-kB inhibitors Na-salicylate (5 mmol/L) and SN-50 (50 mg/mL) (L)i nb-cell death induced by cytokines assessed as in A–D. SN-50 mutant was
used as control for SN-50 treatment. Four to ﬁve experiments were performed in duplicate with islet cell cultures of PancMet KO and WT mice
treated as in D. Results are means 6 SE. *P < 0.05 vs. untreated ^P < 0.05 vs. WT and #P < 0.05 vs. WT or KO treated with cytokines alone or with
SN-50 mutant; assessed by Student t test or one-way ANOVA and Tukey’s honestly signiﬁcant difference post hoc test where appropriate. CKS,
cytokines. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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cluded in this study establish the possibility that alter-
ations in the expression or activation of HGF/c-Met
signaling might further predispose individuals toward the
development of diabetes.
This study found that mice deﬁcient in c-Met in the
pancreas display extensive intraislet lymphocyte inﬁl-
tration after treatment with MLDS. Recent studies indicate
that HGF has potent anti-inﬂammatory effects in multiple
organ systems, including inﬂammatory bowel disease,
airway and kidney inﬂammation, autoimmune myocarditis,
and autoimmune arthritis (20–24). In the kidney, HGF
decreases the expression of chemokines such as Regu-
lated upon Activation, Normal T-cell Expressed and Se-
creted (RANTES) and MCP-1 in mouse models of subtotal
nephrectomy and obstructive nephropathy (24,45). We
found that c-Met-null islets exposed to cytokines display
enhanced secretion of MCP-1 and MIG, which are known
to recruit macrophages and T cells to sites of tissue injury
and infection (46,47). This suggests that 1) the increased
chemokine production in c-Met-null islets might be re-
sponsible for the enhanced insulitis observed in PancMet
b
FIG. 8. Protective effect of HGF on primary human b-cells treated with cytokines. A: Representative images of human islet cell cultures treated
with 100 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g for 24 h in the absence or (B) presence of 25 ng/mL HGF and stained for
TUNEL (green), insulin (red), and DAPI (blue). Arrows indicate TUNEL-positive b-cell nuclei. Scale bar = 25 mm. C: Quantitation of TUNEL-
positive b-cell nuclei in ﬁve experiments per duplicate performed with human islet cell cultures from ﬁve different donors treated with 50 or 100
units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g for 24 h. D: Representative Western blots displaying the expression of phospho-
and total p65, phospho- and total IkB, phospho-GSK-3b, phospho-AKT, and tubulin in protein extracts from human islets treated with or without
HGF and 100 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g. E: Densitometric quantitation of these proteins in four Western
blots performed with four different human islet extract samples per time point obtained from four different donors. F: Activation of p65/NF-kBi n
human islet extracts treated with 50 units/mL IL-1b, 1,000 units/mL TNF-a, and 1,000 units/mL IFN-g for 10 min and with or without 25 ng/mL HGF
and assessed by an ELISA-based TransAM assay measuring p65/NF-kB binding activity (see RESEARCH DESIGN AND METHODS). In some cases, human
islets were pretreated for 30 min with 10 nM Wortmannin. Results are means 6 SEM of three experiments in triplicate. *P < 0.05 and **P < 0.01 vs.
untreated and ^P < 0.05 vs. cytokine treated. CKS, cytokines; ns, not signiﬁcant. (A high-quality digital representation of this ﬁgure is available in
the online issue.)
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signaling is an endogenous regulator of islet inﬂammation.
However, it is also possible that the increased sensitivity to
b-cell death in PancMet KO mice is an important contrib-
utor to enhanced islet inﬂammation.
NF-kB regulates the expression of genes involved in
cellular stress responses, cell growth, inﬂammation, sur-
vival, and apoptosis (48). The predominant species in NF-
kB pathway in most cell types is the p65:p50 heterodimer,
which associates with the inhibitors of NF-kB( I kBs) in the
cytoplasm of resting cells. Activation of NF-kB mainly
occurs via IKK-mediated phosphorylation of inhibitory
molecules, including IkBa. However, optimal induction of
NF-kB target genes also requires phosphorylation of NF-
kB proteins, such as p65, within their transactivation
domain by a variety of kinases, including protein kinase
A, protein kinase Cz, and glycogen synthase kinase-3
(GSK-3). NF-kB activation is a key event for b-cell de-
struction in vitro after cytokine treatment (31,32). How-
ever, the role of NF-kB in the b-cell in vivo during islet
inﬂammation and autoimmunity remains uncertain. Mice
in which signaling of the entire family of NF-kB/Rel tran-
scription factors is speciﬁcally and conditionally inhibited
in adult b-cells by expressing a dominant-negative form of
IkBa in the b-cell under the control of the tetracycline (on/
off) system display nearly complete protection against
MLDS-induced diabetes (33). Our studies found that c-Met-
null islets display increased p65 phosphorylation com-
pared with WT islets after treatment with cytokines. This
increase in NF-kB activation could be responsible for the
enhanced NO and chemokine production and intraislet
inﬁltration, and the increased b-cell sensitivity to cytokines
in PancMet KO mouse islets. Conversely, HGF treatment
downregulated the NF-kB-iNOS-NO pathway in normal
mouse islets. Inhibiting NOS with L-NMMA or blocking the
degradation of the NF-kB inhibitor, IkB, with salicylate or
inhibition of NF-kB nuclear translocation with SN-50
clearly eliminated cytokine-induced b-cell death in WT
islets and in c-Met-null islets. These results suggest that
HGF/c-Met signaling might act as a regulator of NF-kB-
iNOS-NO pathway in b-cells in the presence of cytokines.
These results could also suggest that c-Met deﬁciency in
b-cells of NOD mice could accelerate diabetes onset in
NOD-PancMet KO mice. However, NOD–RIP–mIkBa mice
expressing a nondegradable form of IkBa in pancreatic
b-cells display accelerated diabetes onset, indicating that
NF-kB may play an antiapoptotic role in NOD mouse
b-cells and protects from developing diabetes (49). Future
studies describing whether c-Met absence from b-cells
affects diabetes onset in NOD mice are warranted.
Recent evidence indicates that HGF disrupts NF-kB
signaling in endothelial and renal tubule cells by IkB and
GSK-3–dependent mechanisms (24,45,50). HGF decreased
p65/NF-kB activation, diminished IkBa phosphorylation,
and increased Akt and GSK-3 phosphorylation in cytokine-
treated human islets. HGF-mediated inhibition of cytokine-
induced p65/NF-kB activation was reduced by the PI3K
inhibitor Wortmannin, indicating that both aspects of NF-
kB inactivation—sequestration of NF-kB and decreased
kinase-induced activation—might be involved in the effect
of HGF in human islets. Taken together, these results
suggest that HGF-mediated protection of b-cells is likely
through downregulation of NF-kB signaling pathway.
In conclusion, although HGF/c-Met signaling in the pan-
creas is dispensable for normal b-cell growth, function, and
maintenance, its absence renders b-cells highly susceptible
to cell death against diabetogenic agents. These observa-
tions also highlight a novel role for HGF as a protector of
mouse and, more important, human b-cells against cyto-
kines. Collectively, these results point out the physiologic
and therapeutic importance of the entire HGF/c-Met path-
way for the survival of the b-cell in diabetes.
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